DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Azacytidine is an investigational drug.
There have been 124 clinical trials for Azacytidine. The most recent clinical trial was a Phase 3 trial, which was initiated on August 13th 2019.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.
Recent Clinical Trials for Azacytidine
|Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission||National Cancer Institute (NCI)||Phase 2|
|Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission||M.D. Anderson Cancer Center||Phase 2|
|Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy||Tolero Pharmaceuticals, Inc.||Phase 2|